Spironolactone After Liver Transplant

Wake Forest University Health Sciences30 enrolled

Overview

To study spironolactone to prevent calcineurin inhibitor (CNI) kidney injury.

The aim of this study is to determine if spironolactone decreases nephrotoxicity from calcineurin inhibitors in liver transplant recipients and to determine the best study of renal function in liver transplant recipients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Transplant, Liver

Interventions

SpironolactoneDRUG

spironolactone 25 mg up to 50 mg

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 Years

Medical Language ↔ Plain English

Inclusion Criteria: * liver transplant Exclusion Criteria: * dual organ transplant

Locations (1)

CHS

Charlotte, North Carolina, United States

Outcomes

Primary Outcomes

Glomerular Filtration Rate (GFR)

The primary analyses were based on the difference between each estimated GFR measure and iothalamate scan.

Time frame: 18 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.